Key result
Non-potassium-sparing diuretics remain the cornerstone of HF fluid management despite high-dose mortality risks.
Why the study?
Non-potassium-sparing diuretics remain the cornerstone for fluid management in heart failure despite lack of large randomized trials evaluating their safety and optimal dosing.
While non-potassium-sparing diuretics remain essential for fluid management in heart failure, their potential adverse effects highlight the need for alternative therapies and combination with aldosterone blocking agents.
Answers are grounded in this paper and cite their sources.
Diuretics remain essential for HF decongestion; leaves open prospective trials clarifying high-dose risks and alternatives.
Hospitalization for heart failure is a major health problem with high in-hospital and postdischarge mortality and morbidity. Non-potassium-sparing diuretics (NPSDs) still remain the cornerstone of therapy for fluid management in heart failure despite the lack of large randomized trials evaluating their safety and optimal dosing regimens in both the acute and chronic setting. Recent retrospective data suggest increased mortality and re-hospitalization rates in a wide spectrum of heart failure patients receiving NPSDs, particularly at high doses. Electrolyte abnormalities, hypotension, activation of neurohormones, and worsening renal function may all be responsible for the observed poor outcomes. Although NPSD will continue to be important agents to promptly resolve signs and symptoms of heart failure, alternative therapies such as vasopressine antagonists and adenosine blocking agents or techniques like veno-venous ultrafiltration have been developed in an effort to reduce NPSD exposure and minimize their side effects. Until other new agents become available, it is probably prudent to combine NPSD with aldosterone blocking agents that are known to improve outcomes.
No takes yet. Share an insight, caveat, or question.
Brandimarte et al. (2010) conducted a review in Heart failure. Non-potassium-sparing diuretics (NPSDs) was evaluated. Non-potassium-sparing diuretics remain the cornerstone of fluid management in heart failure despite retrospective data suggesting increased mortality and re-hospitalization rates at high doses.
Synapse has enriched 10 related papers. Consider them for comparative context: